Hexagon Bio
hexagonbio.com
Actively hiring
Drug Discovery
Oncology Therapeutics
Biologics & Biosimilars
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$146.6M
4 rounds on record
Latest round
$77.3M
Series B · Feb 2023 · 3 yr ago
Team
70
US Form 5500 (plan participants) · Dec 2024
Hiring now
1
+1 posted in 30 days
Backers
1
Nextech Invest
The money's age
Long since its last round
43 months since the last round · and hiring
Momentum
13/100
hiring for its size
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Nov 26, 2024
Board appointment Hexagon Bio Appoints Yujiro Hata to Board of Directors · YahooFinance
Feb 13, 2023
Raised a round Series B $77.3M · YahooFinance
Jun 11, 2021
Raised a round Venture round $61M · SEC Form D
Apr 9, 2018
Took on debt financing $12M · SEC Form D
Jun 16, 2017
Raised a round Venture round $8.3M · SEC Form D
2016
Founded
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Feb 2023 | $77.3M | — | YahooFinance |
| Venture round | Jun 2021 | $61M | — | SEC Form D |
| Debt Financing | Apr 2018 | $12M | — | SEC Form D |
| Venture round | Jun 2017 | $8.3M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Hexagon Bio Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Colin James HarveyExecutive Officer, DirectorSEC Form D
Brian NaughtonExecutive Officer, DirectorSEC Form D
Maureen HillenmeyerExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Nextech Invest Similar startupsby what they do, their industry and backers
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
At ITM, precision drives everything - from isotope manufacturing to cancer treatment—improving outcomes and delivering what patients and…
We are solving a major bottleneck in the field of targeted biotherapeutics in oncology – the identification of novel targets for the…
Discover how Day One Biopharmaceuticals is disrupting the status quo of traditional drug development to bring new medicines to children and…
News
Hexagon Bio Announces Formation of Clinical Advisory Board of Renowned Breast Cancer Experts to Support Development of HEX-360, a Next-Generation HER2-Targeting ADC
-HEX-360's novel translation inhibitor payload is designed to overcome resistance and poor tolerability associated with existing payload classes -Recently presented preclinical data at the AACR Annual Meeting 2026 demonstrates HEX-360's potential to addre
Read more
Report
Hexagon Bio Announces Formation of Clinical Advisory Board of Renowned Breast Cancer Experts to Support Development of HEX-360, a Next-Generation HER2-Targeting ADC
The post Hexagon Bio Announces Formation of Clinical Advisory Board of Renowned Breast Cancer Experts to Support Development of HEX-360, a Next-Generation HER2-Targeting ADC appeared first on Hexagon.
Read more
Report
HER2-Translation Inhibitor ADC: A Development Candidate ADC Featuring a Novel Translation Inhibitor Payload With Broad Efficacy and a Favorable Non Human Primate Safety Profile
The post HER2-Translation Inhibitor ADC: A Development Candidate ADC Featuring a Novel Translation Inhibitor Payload With Broad Efficacy and a Favorable Non Human Primate Safety Profile appeared first on Hexagon.
Read more
Report
The Development Path of a HER2-Targeted Translation Inhibitor ADC: A Novel Payload and ADC to Address a Growing Clinical Need
The post The Development Path of a HER2-Targeted Translation Inhibitor ADC: A Novel Payload and ADC to Address a Growing Clinical Need appeared first on Hexagon.
Read more
Report
Protein Translation Inhibitors (PTIs) Enable Next-Generation Antibody Drug Conjugates
The post Protein Translation Inhibitors (PTIs) Enable Next-Generation Antibody Drug Conjugates appeared first on Hexagon.
Read more
Report
Pro access
Upgrade to see all 15 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Tech stack
Technologies named in job postings at Hexagon Bio over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$325k
Typical range
$325k
Open positions
1
1
Jobs
Senior
100%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 1 | $325k | $325k |
Highest paying role
Sr./Ex. Director or VP, Clinical Scientist (PhD or PharmD equivalent)
$325k
Normalized to USD per year
People
Colin James Harvey
Executive Officer, Director
Brian Naughton
Executive Officer, Director
Maureen Hillenmeyer
Executive Officer, Director
Alex Kolich
Director
Alex Kolicich
Director
David Goeddel
Director
Juan Jaen
Director
Mridula Ray
Director
Jakob Loven
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~10 hours
09/29/2026
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▲
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Menlo Park
Menlo Park
United States
HQ
Partner with us
1 open roles 1 posted in 90 days 100% engineering 200-500 est. staff $325k Avg Salary
hires for Science & Research
1490 O’Brien Drive, Suite E, Menlo Park, CA 94025